LEUCOVORIN AND 5-FLUOROURACIL AS A TREATMENT FOR DISSEMINATED CANCER OF THE PANCREAS AND UNKNOWN PRIMARY TUMORS
- 1 October 1988
- journal article
- research article
- Vol. 48 (19) , 5570-5572
Abstract
Chemotherapy with leucovorin (100 to 200 mg) and 5-fluorouracil (30 mg/kg) every 2 wk produced four (three complete) objective responses among a group of eight patients with early metastatic pancreatic primary and unknown cancers. Complete remissions were associated with exceptionally long durations of survival, one in a patient failing prior combination chemotherapy. This treatment warrants testing because of its ease, scientific rationale, and the large population of patients with early metastatic pancreatic cancer for whom there is no accepted treatment. Early metastatic disease is defined as small metastatic lesions not immediately life threatening found in a physiologically intact patient. Controlled trials, demonstrating benefit associated with other 5-fluorouracil-containing regimens for patients with nonmetastatic stages of pancreatic cancer, provide a rationale for extending testing of leucovorin and 5-fluorouracil to other early stages of pancreatic cancer.This publication has 3 references indexed in Scilit:
- PHASE-I-II TRIAL OF HIGH-DOSE CALCIUM LEUCOVORIN AND 5-FLUOROURACIL IN ADVANCED COLORECTAL-CANCER1984
- TREATMENT OF ADVANCED COLORECTAL AND GASTRIC ADENOCARCINOMAS WITH 5-FU COMBINED WITH HIGH-DOSE FOLINIC ACID - A PILOT-STUDY1982
- Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The gastrointestinal tumor study groupCancer, 1981